Finance

Mga Listahan
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
$301.79
+1.27%
(+3.79) 1D
$301.79
0.00% (0.00)
Pagkalipas ng oras ng trabaho
Sarado: Okt 9, 4:00:05 PM GMT-4  ·   USD
Lahat ng simbolo
SimboloPresyoPalitan% ng Pagbabago
Bumubuo ng mga nangungunang insight para sa CRL...
Buksan
$294.60
Mataas
$305.20
Mababa
$294.60
Mkt. cap
14.41B
Avg. na dami
982.10K
Dami
679.86K
Mataas nang 52-wk
$333.30
Mababa nang 52-wk
$146.20
EPS
-$4.85
Beta
1.40
Mga natitirang share
47.74M
Bilang ng mga empleyado
19K
Buksan
$294.60
Mataas
$305.20
Mababa
$294.60
Mkt. cap
14.41B
Avg. na dami
982.10K
Dami
679.86K
Mataas nang 52-wk
$333.30
Mababa nang 52-wk
$146.20
EPS
-$4.85
Beta
1.40
Mga natitirang share
47.74M
Bilang ng mga empleyado
19K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
Tungkol sa Charles River Laboratories Intrtnl, Inc.
CEO-
Mga Empleyado19K
Itinatag1947
HeadquartersWilmington, Massachusetts, Estados Unidos
Sektor-
Websitecriver.com
Mga rating ng analyst
Batay sa 16 (na) analyst na nagbigay ng mga rating ng stock sa CRL sa nakalipas na 3 buwan
Strong buy
Pagbili
14
Pag-hold
2
Pagbebenta
0
12 buwang forecas
Batay sa 16 (na) analyst sa Wall Street na nag-aalok ng mga target na presyo sa loob ng 12 buwan para sa CRL sa nakalipas na 3 buwan.
Pinakamataas
Kasalukuyan $301.79
$357.00 (+18.29%)
Average
$316.57 (+4.90%)
Pinakamababa
$219.00 (-27.43%)
Analyst
Rekomendasyon
Aksyon
Target na presyo
Inaasahan
Petsa
Ryan Halsted
RBC Capital
Buy
Maintained
$322.00
+6.7%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
$357.00
+18.3%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
$340.00
+12.7%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
$320.00
+6%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$330.00
+9.3%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
$295.00
-2.2%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$334.00
+10.7%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
$330.00
+9.3%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$325.00
+7.7%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
$320.00
+6%
09/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$300.00
-0.6%
09/21/2026
David Toung
Argus Research
Buy
Reiterated
$330.00
+9.3%
09/16/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
$310.00
+2.7%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
$219.00
-27.4%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
$265.00
-12.2%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
$215.00
-28.8%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
$175.00
-42%
02/25/2026
Huling ulat
Ago 5, 2026
Fiscal period
Q2 2026
$3.02 / $2.74
+10.31%lumampas
Kita / Pagtataya (USD)
1.00B / 977.20M
+2.75%lumampas
Earnings call para sa Fiscal Q2 2026
Hinihintay ang earnings call
Sa isang sulyap
Mga insight mula sa mga pinakabagong balita at ulat
Mga nakaraang ulatLahat ng value sa USD
Loading Previous Earnings...
Kita
Net na kita
Lahat ng value sa USD
Set 2025
Dis 2025
Mar 2026
Hun 2026
Kita
1.00B
994.23M
995.83M
1.00B
Gastusin sa mga naibentang produkto
652.72M
665.36M
672.79M
625.06M
Halaga ng kita
652.72M
665.36M
672.79M
625.06M
Mga gastos sa pananaliksik at pag-develop
-
-
-
-
Kabuuang gastos sa pananaliksik at pag-develop
-
-
-
-
Mga gastos sa pagbebenta, pangkalahatan, at admin
173.64M
192.02M
149.12M
214.18M
Gastos sa pagpapatakbo
201.05M
284.04M
164.46M
227.27M
Kabuuang gastos sa pagpapatakbo
853.77M
949.40M
837.25M
852.33M
Kita sa pagpapatakbo
151.08M
44.83M
158.58M
151.74M
Iba pang hindi kita sa pagpapatakbo
-22.62M
27.72M
-123.11M
25.99M
EBT na may mga hindi karaniwang item
87.20M
-294.10M
-29.94M
53.17M
EBT na hindi kasama ang mga hindi karaniwang item
104.48M
35.18M
8.62M
148.43M
Gastos sa buwis sa kita
31.64M
-17.81M
-15.14M
53.93M
Epektibong rate ng buwis
36.29%
6.06%
50.56%
101.43%
Iba pang gastos sa pagpapatakbo
-
-
-
-
Net na kita
54.42M
-276.56M
-14.84M
-1.48M
Margin ng kabuuang kita
5.42%
-27.82%
-1.49%
-0.15%
Kita bawat share
2.43
2.39
2.06
3.02
Kita sa interes at investment
1.42M
1.02M
1.03M
1.03M
Gastos sa interes
-25.40M
-23.78M
-26.74M
-30.34M
Mga net na gastos sa interes
-23.98M
-22.76M
-25.71M
-29.31M
Mga singil sa depreciation at amortization
-
-
-
-
EBITDA
236.25M
169.61M
225.73M
217.54M
Kita o pagkalugi mula sa pagbebenta ng mga asset
-
-
117.98M
24.92M
Mga transaksyon ng insider
Kinukuha ang data ng mga insider na transaksyon mula sa mga third-party na source. Matuto pa
Insider
Posisyon
Uri
Petsa
Mga Share
Halaga
Page 1
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa
Mga app ng Google